We are live on ! Find out more
FCMI

Foresite Capital Management I Portfolio holdings

AUM $21.4M
1-Year Est. Return 80.48%
This Fund
S&P 500
This Quarter Est. Return
+42.73%
1 Year Est. Return
-80.48%
3 Year Est. Return
-40.72%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$317M
AUM Growth
-$44.2M
Cap. Flow
-$174M
Cap. Flow %
-54.84%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$4.25M

Top Sells

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$178M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.55B
$313M 98.53%
3,500,000
-2,288,317
-40% -$178M
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$3.92M 1.23%
+243,759
New +$4.25M
XLRN
3
DELISTED
Acceleron Pharma
XLRN
$762K 0.24%
8,000
– –

Similar funds

A
Atlassian San Francisco, California $21M AUM 71.86% 1-Year Est. Return
CVGI
Craft Ventures GP II San Francisco, California $24.1M AUM 83.06% 1-Year Est. Return
AEPI
AH Equity Partners IV Menlo Park, California $24.5M AUM 73.4% 1-Year Est. Return
AGDR
AdamCapital Gestao de Recursos Rio De Janeiro, Brazil $18.1M AUM 32.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
WL
WiL LLC Palo Alto, California $17.5M AUM 75.04% 1-Year Est. Return
NVPX
Norwest Venture Partners XIII Palo Alto, California $25.8M AUM 76.52% 1-Year Est. Return
SVGI
Sozo Ventures GP I Redwood City, California $16.3M AUM 66.18% 1-Year Est. Return

Foresite Capital Management I's Q2 2020 Portfolio in Review

As of Q2 2020, Foresite Capital Management I held 3 positions worth $317M, down 12% from $361M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management I withdrew a net $174M in Q2 2020, reducing 1 holding. Its largest reduction was 10x Genomics, cutting an estimated $178M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management I opened a new position in Epizyme, Inc worth $3.92M.

  • Foresite Capital Management I's largest Q2 2020 buy was Epizyme, Inc: 243,759 shares worth $3.92M.
  • Foresite Capital Management I's biggest Q2 2020 reduction was 10x Genomics, cutting an estimated $178M.
  • Foresite Capital Management I's ten largest holdings make up 100% of its $317M portfolio in Q2 2020.
  • Foresite Capital Management I opened 1 new position and closed 0 in Q2 2020.
  • Foresite Capital Management I's portfolio value fell 12% quarter-over-quarter to $317M.

Based on Foresite Capital Management I's 13F filing for Q2 2020, filed 13 Aug 2020.